Tanja Obradovic: Orum Therapeutics is focusing its innovation pipeline on degrader-antibody conjugates

Tanja Obradovic shared a post on LinkedIn:

“Great news from Orum Therapeutics, a Korea based biotech has been just announced. It is filing for an initial public offering (IPO) on South Korea’s Kosdaq market.

Company is focusing it innovation pipeline on degrader-antibody conjugates (DACs). Orum’s proprietary Dual-precision Targeted Protein Degradation (TPD) approach uses antibodies to deliver small molecule targeted protein degrader payloads to targeted cancer cells. The TPD technology produced two most advanced products.

ORM-5029 (targets HER2) and ORM-6151 (targets CD33 and acquired by BMS). Great news and very interesting potential for the new therapeutic modality. South Korea’s biotech industry is definitively experiencing rapid growth.”

Additional information

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.